| AdvSM | Advanced systemic mastocytosis |
| BM | Bone marrow |
| CR | Complete remission/response |
| CRh | Complete response with partial hematologic recovery |
| ECNM | European Competence Network on Mastocytosis |
| EMA | European Medicines Agency |
| FDA | Food and Drug Administration |
| HαT | Hereditary alpha-tryptasemia |
| ISM | Indolent systemic mastocytosis |
| IWG-MRT-ECN | International Working Group-Myeloproliferative Neoplasms Research and Treatment |
| MC | Mast cells |
| MCL | Mast cell leukemia |
| mIWG-MRT-ECNM | Modified International Working Group-Myeloproliferative Neoplasms Research and Treatment |
| MR | Major response |
| PPR | Pure pathologic response |
| PR | Partial response |
| SM | Systemic mastocytosis |
| SM-AHN | Systemic mastocytosis with an associated hematologic neoplasm |
| SSM | Smoldering systemic mastocytosis |
| WHO | World Health Organization |